Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2008Vascular Health and Risk ManagementOpen Access

Update on the use of Trandolapril in the management of cardiovascular disorders

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does trandolapril improve clinical outcomes in patients with cardiovascular disorders such as post-AMI left ventricular dysfunction, hypertension, and diabetes?

Population

Patients with cardiovascular disorders including congestive heart failure after acute myocardial infarction…

Design

Review

Authors

ADAnique DucharmeHeart Failure & Transplant

Discussion

Loading...

Member takes

Overview

Supports trandolapril post-AMI with reduced LVEF; leaves open its role versus contemporary therapies.

Structured PICO

Does trandolapril improve clinical outcomes in patients with cardiovascular disorders such as post-AMI left ventricular dysfunction, hypertension, and diabetes?

P
Population
Patients with cardiovascular disorders including congestive heart failure (CHF) after acute myocardial infarction (AMI), diabetes, hypertension (HTN), stable coronary artery disease (CAD), and those at risk for proteinuria.
I
Intervention
Trandolapril (once-a-day administration)

Trandolapril is an effective once-daily ACE inhibitor with proven mortality and morbidity benefits across a wide spectrum of cardiovascular conditions, particularly in post-AMI left ventricular dysfunction and diabetic nephropathy.

Cite This Study

Anique Ducharme (2008) studied this question.

synapsesocial.com/papers/6a8bb95490fae8fd47e98d35https://doi.org/10.2147/vhrm.s3467

Topics

Heart failureHFrEF treatmentCoronary artery diseaseHypertension management
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril2000 · 23 citations
  2. 2Urinary albumin excretion — A predictor of risk of cardiovascular disease A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men1996 · 134 citations